InvestorsHub Logo
Followers 0
Posts 96
Boards Moderated 0
Alias Born 06/17/2015

Re: tredenwater2 post# 279225

Thursday, 10/29/2020 12:31:34 PM

Thursday, October 29, 2020 12:31:34 PM

Post# of 470797
Agreed. It's Biogen paying to drive excitement and put more pressure on the FDA. Found this in a Motley Fool article published 2 days ago:

Ever since Biogen (NASDAQ:BIIB) revived a phase 3 Alzheimer's program a year ago, investors have been waiting with bated breath for the next steps. The company submitted aducanumab, the investigational Alzheimer's treatment, for regulatory review in July. Now, an advisory committee is set to meet on Nov. 6 to weigh in on whether the U.S. Food and Drug Administration (FDA) should approve the drug candidate.

https://www.fool.com/investing/2020/10/27/why-an-upcoming-fda-meeting-is-critical-for-biogen/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News